765 related articles for article (PubMed ID: 34871388)
1. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
[TBL] [Abstract][Full Text] [Related]
2. Effect of anti-SARS-CoV-2 BNT162b2 mRNA vaccination on thrombin generation in children with inflammatory bowel disease.
Stercel V; Lóczi L; Kadenczki O; Nemes É; Nagy B; Hodossy-Takács R; Szabó AÁ; Fagyas M; Kappelmayer J; Szabó T; Bagoly Z
Front Immunol; 2023; 14():1257072. PubMed ID: 37965328
[TBL] [Abstract][Full Text] [Related]
3. Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis.
James D; Jena A; Bharath PN; Choudhury A; Singh AK; Sebastian S; Sharma V
Dig Liver Dis; 2022 Jun; 54(6):713-721. PubMed ID: 35382972
[TBL] [Abstract][Full Text] [Related]
4. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
[TBL] [Abstract][Full Text] [Related]
5. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
[TBL] [Abstract][Full Text] [Related]
6. Differences in Coronavirus disease - 19 vaccination related side effects in patients with ulcerative colitis and Crohn's disease in Japan.
Miyazaki H; Watanabe D; Ito Y; Ikeda S; Okamoto N; Tokunaga E; Ku Y; Ooi M; Hoshi N; Kodama Y
Indian J Gastroenterol; 2023 Oct; 42(5):701-707. PubMed ID: 37505394
[TBL] [Abstract][Full Text] [Related]
7. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications.
Khan N; Mahmud N
Gastroenterology; 2021 Sep; 161(3):827-836. PubMed ID: 34048782
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N;
Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954
[TBL] [Abstract][Full Text] [Related]
10. Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease.
Markovinović A; Quan J; Herauf M; Hracs L; Windsor JW; Sharifi N; Coward S; Caplan L; Gorospe J; Ernest-Suarez K; Ma C; Panaccione R; Ingram RJM; Kanji JN; Tipples G; Holodinsky JK; Bernstein CN; Mahoney DJ; Bernatsky S; Benchimol EI; Kaplan GG; ;
Am J Gastroenterol; 2023 Sep; 118(9):1693-1697. PubMed ID: 37216598
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis.
Sung KY; Chang TE; Wang YP; Lin CC; Chang CY; Hou MC; Lu CL
J Chin Med Assoc; 2022 Apr; 85(4):421-430. PubMed ID: 34974509
[TBL] [Abstract][Full Text] [Related]
12. Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey.
Ellul P; Revés J; Abreu B; Chaparro M; Gisbert JP; Allocca M; Fiorino G; Barberio B; Zingone F; Pisani A; Cassar D; Michalopoulos G; Mantzaris G; Koutroubakis I; Karmiris K; Katsanos K; Ďuricova D; Burisch J; Madsen GR; Maaser C; Naila A; Orfanoudaki E; Milivojevic V; Buisson A; Avedano L; Leone S; Torres J
J Crohns Colitis; 2022 Aug; 16(7):1070-1078. PubMed ID: 35037033
[TBL] [Abstract][Full Text] [Related]
13. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
[TBL] [Abstract][Full Text] [Related]
14. Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease.
Kastl AJ; Weaver KN; Zhang X; Strople JA; Adler J; Kelsen JR; Dubinsky MC; Bousvaros A; Watkins R; Dai C; Cross RK; Higgins PDR; Ungaro R; Bewtra M; Bellaguarda EA; Farraye FA; Chun K; Zikry M; Bastidas M; Boccieri ME; Firestine A; Long MD; Kappelman MD
J Pediatr Gastroenterol Nutr; 2024 Apr; 78(4):871-877. PubMed ID: 38356293
[TBL] [Abstract][Full Text] [Related]
15. Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection.
Motwani KK; Hashash JG; Farraye FA; Kappelman MD; Weaver KN; Zhang X; Long MD; Cross RK
J Crohns Colitis; 2023 Nov; 17(10):1681-1688. PubMed ID: 37232444
[TBL] [Abstract][Full Text] [Related]
16. Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study.
Shehab M; Alrashed F; Abdullah I; Alfadhli A; Ali H; Abu-Farha M; Channanath AM; Abubaker JA; Al-Mulla F
Front Med (Lausanne); 2022; 9():881027. PubMed ID: 35755075
[TBL] [Abstract][Full Text] [Related]
17. Low vaccination and infection rate of Omicron in patients with inflammatory bowel disease: a comparative study of three unique cohorts.
Feng J; Yang T; Yao R; Feng B; Hao R; Qiao Y; Tong J; Shen J
Front Public Health; 2023; 11():1115127. PubMed ID: 37397758
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
19. Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type.
Jørgensen KK; Høivik ML; Chopra A; Benth JŠ; Ricanek P; Moum PB; Jyssum I; Bolstad N; Warren DJ; Vaage PJT; Munthe PLA; Lundin PKEA; Anisdahl K; Syversen SW; Goll GL; Lund-Johansen F; Medhus AW; Jahnsen PJ
Scand J Gastroenterol; 2023; 58(8):874-882. PubMed ID: 36788656
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccinations and infections among individuals with systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study.
Lakin KS; Wu Y; Gordon JK; Kwakkenbos L; Carrier ME; Henry RS; Denton CP; Mouthon L; Spiera RF; Thombs BD; ;
Semin Arthritis Rheum; 2024 Aug; 67():152453. PubMed ID: 38851172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
